Abstract
Many aspects of tuberoinfundibular dopaminergic neuronal function are increased by elevated prolactin (PRL) levels, including the activity of tyrosine hydroxylase, the rate-limiting enzyme in the biosynthesis of dopamine. This study evaluated the roles of calmodulin, cyclic nucleotide-dependent protein kinase, and calcium/calmodulin-dependent protein kinase II in the PRL-induced increase in tyrosine hydroxylase activity. Ovariectomizerd rats were treated with haloperidol or ovine PRL (oPRL) for 20–30 h before the experiment, respectively. Treatment with haloperidol increased circulating PRL levels 8-fold and tyrosine hydroxylase activity in the stalk-median eminence 1.8-fold. Treatment with oPRL increased tyrosine hydroxylase activity 1.9-fold. W-7, a calmodulin antagonist, reversed both the haloperidol- and oPRL-induced increase in tyrosine hydroxylase activity to control levels. H-8, a cyclic nucleotide-dependent protein kinase inhibitor, also reversed the haloperidol induced increase in tyrosine hydroxylase activity. KN62, a selective calcium/calmodulin-dependent protein kinase II inhibitor, attenuated the haloperidol-induced increase in tyrosine hydroxylase activity, but KNO4, a structurally related control compound, had no effect. By contrast, the oPRL- and haloperidol-induced increases in tyrosine hydroxylase activity were not altered by KN93, a selective calcium/calmodulin-dependent protein kinase II inhibitor. These data indicate that calmodulin and a cyclic nucleotide-dependent protein kinase contribute to the PRL-induced increase in tyrosine hydroxylase activity, but the role of calcium/calmodulin-dependent protein kinase II is still unclear.
Similar content being viewed by others
References
Ben-Jonathan, N. (1994). Endocr. Rev. 6, 564–589.
Moore, K. E. (1987). Biol. Reprod. 36, 47–58.
Arbogast, L. A. and Voogt, J. L. (1991). Endocrinology 128, 997–1005.
Selmanoff, M., Shu, C., Hartman, R. D., Barraclough, C. A., and Petersen, S. L. (1991). Mol. Brain Res. 10, 277–281.
Selmanoff, M. (1985). Endocrinology 116, 1943–1952.
Demarest, K. T., Riegle, G. D., and Moore, K. E. (1986). Neuroendocrinology 43, 291–299.
Gudelsky, G. A. and Porter, J. C. (1980). Endocrinology 106, 526–529.
Arbogast, L. A. and Voogt, J. L. (1997). Endocrinology 138, 3016–3023.
Lerant, A. and Freeman, M. E. (1998). Brain Res. 802, 141–154.
Hentschel, K., Cheung, S., Moore, K. E., and Lookingland, K. J. (1998). Neuroendocrinology 68, 71–76.
Levitt, M., Spector, S., Sjoerdsma, A., and Udenfriend, S. (1965). J. Pharmacol. Exp. Ther. 148, 1–8.
Masserano, J. M. and Weiner, N. (1983). Mol. Cell. Biochem. 53/54, 129–152.
Zigmond, R. E., Schwarzschild, M. A., and Rittenhouse, A. R. (1989). Annu. Rev. Neurosci. 12, 415–461.
Kumer, S. C. and Vrana, K. E. (1996). J. Neurochem. 67, 443–462.
Haycock, J. W. and Wakade, A. R. (1992). J. Neurochem. 58, 57–64.
Campbell, D. G., Hardie, D. G., and Vulliet, P. R. (1986). J. Biol. Chem. 261, 10,489–10,492.
Vulliet, P. R., Woodgett, J. R., Ferrari, S., and Hardie, D. G. (1985). FEBS Lett. 182, 335–339.
Haycock, J. W., Ahn, N. G., Cobb, M. H., and Krebs, E. G. (1992). Proc. Natl. Acad. Sci. USA 89, 2365–2369.
Arbogast, L. A. and Voogt, J. L. (1995). Endocrine 3, 801–806.
Hentschel, K., Fleckenstein, A. E., Toney, T. W., Lawson, D. M., Moore, K. E., and Lookingland, K. J. (2000). Brain Res. 852, 28–36.
Pasqualini, C., Guibert, B., Frain, O., and Leviel, V. (1994). J. Neurochem. 62, 967–977.
Arita, J. and Kimura, F. (1986). Endocrinology 119, 1666–1672.
Imai, S. and Onozuka, M. (1988). Comp. Biochem. Physiol. C 91, 535–540.
Hidaka, H., Inagaki, M., Kawamoto, S., and Sasaki, Y. (1984). Biochemistry, 23, 5036–5041.
Tokumitsu, H., Chijiwa, T., Hagiwara, M., Mizutani, A., Terasawa, M., and Hidaka, H. (1990). J. Biol. Chem. 265, 4315–4320.
Sumi, M., Kiuchi, K., Ishikawa, T., Ishii, A., Hagiwara, M., Nagatsu, T., and Hidaka, H. (1991). Biochem. Biophys. Res. Commun. 181, 968–975.
DeMaria, J. E., Lerant, A. A., and Freeman, M. E. (1999). Brain. Res. 837, 236–241.
Atkinson, J., Richtand, N., Schworer, C., Kuczenski, R., and Soderling, T. (1987). J. Neurochem. 49, 1241–1249.
Kizer, J. S., Humm, J., Nicholson, G., Greeley, G., and Young-blood, W. (1978). Brain Res. 146, 95–107.
Durham, R. A., Eaton, M. J., Moore, K. E., and Lookingland, K. J. (1997). Eur. J. Pharmacol. 335, 37–42.
Albarracin, C. T., Palfrey, H. C., Duan, W. R., Rao, M. C., and Gibori, G. (1994). J. Biol. Chem. 269, 7772–7776.
Hidaka, H., Sasaki, Y., Tanaka, T., Endo, T., Ohno, S., Fujii, Y., and Nagata, T. (1981). Proc. Natl. Acad. Sci. USA 78, 4354–4357.
Greenberg, D. A., Carpenter, C. L., and Messing, R. O. (1987). Brain Res. 404, 401–404.
Schofl, C., Mader, T., Kramer, C., Waring, M., Krippeit-Drews, P., Prank, K., von zur Muhlen, A., Drews, G., and Brabant, G. (1999). Endocrinology 140, 5516–5523.
Jan, C.-R. and Tseng, C.-J. (2000). J. Pharmacol. Exp. Ther. 292, 358–365.
Sorin, B., Vacher, A. M., Djiane, J., and Vacher, P. (2000). J. Neuroendocrinol. 12, 910–918.
Li, G., Hidaka, H., and Wollheim, C. B. (1992). Mol. Pharmacol. 42, 489–498.
Tsutsui, M., Yanagihara, N., Fukunaga, K., Minami, K., Nakashima, Y., Kuroiwa, A., Miyamoto, E., and Izumi, F. (1996). J. Neurochem. 66, 2517–2522.
Parker Botelho, L. H., Rothermel, J. D., Coombs, R. V., and Jastorff, B. (1988). Methods Enzymol. 159, 159–172.
Hidaka, H. and Kobayashi, R. (1992). Annu. Rev. Pharmacol. Toxicol. 32, 377–397.
Harris, J. E., Baldessarini, R. J., Morgenroth, V. H. III, and Roth, R. H. (1975). Proc. Natl. Acad. Sci. USA 72, 789–793.
Roskoski, R. Jr., Vulliet, P. R., and Glass, D. B. (1987). J. Neurochem. 48, 840–845.
Huang, S. K. and Pan, J. T. (1996). Neuroendocrinology 64, 208–214.
Arbogast, L. A. and Voogt, J. L. (1994). Brain Res. 655, 17–24.
Arbogast, L. A., Shah, G. V., and Voogt, J. L. (1999). Endocrinology 140, 3273–3281.
Waymire, J. C., Craviso, G. L., Lichteig, K., Johnston, J. P., Baldwin, C., and Zigmond, R. E. (1991). J. Neurochem. 57, 1313–1324.
Goncalves, C. A., Hall, A., Sim, A. T., Bunn, S. J., Marley, P. D., Cheah, T. B., and Dunkley, P. R. (1997). J. Neurochem. 69, 2387–2396.
Rui, H., Kirken, R. A., and Farrar, W. L. (1994). J. Biol. Chem. 269, 5364–5368.
Wakao, H., Gouilleux, F., and Groner, B. (1994). EMBO J. 13, 2182–2191.
Campbell, G. S., Argetsinger, L. S., Ihle, J. N., Kelly, P. A., Rillema, J. A., and Carter-Su, C. (1994). Proc. Natl. Acad. Sci. USA 91, 5232–5236.
Watson, C. J. and Burdon, T. G. (1996). Rev. Reprod. 1, 1–5.
Ferrag, F., Goffin, V., Buteau, H., and Kelly, P. A. (1997). Cytokines Cell. Mol. Ther. 3, 197–213.
Lerant, A., Kanyicska, B., and Freeman, M. E. (2001). Brain Res. 904, 259–269.
Hermans, E., Gailly, P., Gillis, J. M., Octave, J. N., and Maloteaux, J. M. (1995). J. Neurochem. 64, 2518–2525.
Zar, J. H. eds. (1984). Biostatistical analysis. Prentice-Hall: Englewood Cliffs, NJ.
Gerald, K. B. (1990). Nurse Anesth. 1, 162–165.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Arbogast, L.A. Calmodulin and a cyclic nucleotide-dependent protein kinase facilitate the prolactin-induced increase in tyrosine hydroxylase activity in tuberoinfundibular dopaminergic neurons. Endocr 16, 105–112 (2001). https://doi.org/10.1385/ENDO:16:2:105
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/ENDO:16:2:105